The Secondary Beneficial Effects of Prostaglandin Analog Treatment in Thyroid Eye Disease Patients.
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT01927406 |
|
Recruitment Status :
Withdrawn
(Funding source unavailable)
First Posted : August 22, 2013
Last Update Posted : May 15, 2018
|
Sponsor:
Stanford University
Information provided by (Responsible Party):
Andrea L Kossler, Stanford University
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Brief Summary:
The purpose of this study is to evaluate the potential secondary beneficial effect of prostaglandin analogues (PA) treatment in thyroid eye disease (TED) patients. This study aims to determine if PA would change the course of the orbitopathy in TED patients by altering the progression of the common features of TED, including fatty hypertrophy, proptosis, eyelid retraction and optic nerve compression. The eyes with thyroid eye disease and elevated intraocular pressure will be randomised to the PA treatment and the other eye will serve as a control eye and will be treated with Timolol.
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Thyroid Eye Disease Ocular Hypertension Glaucoma | Drug: Prostaglandin Analog Drug: Timolol | Phase 4 |
| Study Type : | Interventional (Clinical Trial) |
| Actual Enrollment : | 0 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | Single (Outcomes Assessor) |
| Primary Purpose: | Prevention |
| Official Title: | The Secondary Beneficial Effects of Prostaglandin Analog Treatment in Thyroid Eye Disease Patients. |
| Estimated Study Start Date : | June 2014 |
| Estimated Primary Completion Date : | December 2016 |
| Estimated Study Completion Date : | December 2016 |
Resource links provided by the National Library of Medicine
Genetics Home Reference related topics:
Early-onset glaucoma
| Arm | Intervention/treatment |
|---|---|
|
Experimental: Prostaglandin Analog vs Timolol
In this group, with thyroid eye disease and increased intraocular pressure in both eyes, prostaglandin analog eyedrop (bimatoprost 0.01%, travoprost z 0.004%, tafluprost 0.0015% or latanoprost 0.005%) will be administered once a day, topically, into one - randomised eye. Timolol 0.5% eye drop will be administered topically in second, control eye, two times a day.
|
Drug: Prostaglandin Analog
The first choice drug from group of Prostaglandin Analogues will be bimatoprost, if patient will suffer from any side effect of this drug another drug from this group will be administer. If patient turned out to cannot tolerate the prostaglandin analog therapy then the exclusion criteria will be met.
Other Names:
Drug: Timolol Timolol topical eye drop will be administered in Prostaglandin Analog vs Timolol arm only, in patients with elevated intraocular pressure in both eyes.
Other Name: Timolol maleate 0.5% |
|
Experimental: Prostaglandin Analog
In this group, with thyroid eye disease and increased intraocular pressure in only one eye Prostaglandin Analog eyedrop (bimatoprost 0.01%, travoprost z 0.004%, tafluprost 0.0015% or latanoprost 0.005%) will be administered once a day, topically, into one, affected eye.
|
Drug: Prostaglandin Analog
The first choice drug from group of Prostaglandin Analogues will be bimatoprost, if patient will suffer from any side effect of this drug another drug from this group will be administer. If patient turned out to cannot tolerate the prostaglandin analog therapy then the exclusion criteria will be met.
Other Names:
|
Primary Outcome Measures :
- Change from baseline in appearance of facial periorbital region at 6 months. [ Time Frame: Baseline and 6 months ]
Secondary Outcome Measures :
- Change from baseline in Hertel exophthalmometry at 3, 6, 9 and 12 months. [ Time Frame: Baseline and 3, 6, 9 and 12 months ]
- Change from baseline in intraocular pressure at 3, 6, 9 and 12 months. [ Time Frame: Baseline and 3, 6, 9 and 12 months ]
- Change from baseline in appearance of facial periorbital region at 3, 6, 9 and 12 months. [ Time Frame: Baseline and 3, 6, 9 and 12 months ]
Information from the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- mild or moderate to severe thyroid eye disease in one or both eyes
- age > 18 years
- informed consent
- intraocular pressure > 21 mmHg or glaucoma suspect or glaucoma diagnosed in one or both eyes
- not on current prostaglandin analog intraocular pressure lowering therapy
Exclusion Criteria:
- sight threatening thyroid eye disease
- children < 18 years old
- patients that are not compliant with treatment or follow-up
- patients already on prostaglandin analog treatment
- patients that undergo cosmetic periocular procedures during the study will be excluded from further follow up
- patients that cannot tolerate prostaglandin analog treatment.
- patients with bilateral thyroid eye disease and elevated intraocular pressures that cannot tolerate treatment with timolol or an alternative intraocular pressure lowering medication such as trusopt, combigan, cosopt.
Information from the National Library of Medicine
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01927406
Locations
| United States, California | |
| Stanford Hospital and Clinics | |
| Stanford, California, United States, 94304 | |
Sponsors and Collaborators
Stanford University
Investigators
| Principal Investigator: | Andrea L. Kossler, M.D. | Stanford University |
| Responsible Party: | Andrea L Kossler, M.D., Stanford University |
| ClinicalTrials.gov Identifier: | NCT01927406 History of Changes |
| Other Study ID Numbers: |
26654 |
| First Posted: | August 22, 2013 Key Record Dates |
| Last Update Posted: | May 15, 2018 |
| Last Verified: | May 2018 |
Keywords provided by Andrea L Kossler, Stanford University:
|
Thyroid Eye Disease Graves' Disease Prostaglandin Analogues |
Additional relevant MeSH terms:
|
Thyroid Diseases Ocular Hypertension Eye Diseases Graves Ophthalmopathy Endocrine System Diseases Eye Diseases, Hereditary Graves Disease Exophthalmos Orbital Diseases Goiter Hyperthyroidism Autoimmune Diseases Immune System Diseases |
Timolol Latanoprost Bimatoprost Travoprost Adrenergic beta-Antagonists Adrenergic Antagonists Adrenergic Agents Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action Physiological Effects of Drugs Anti-Arrhythmia Agents Antihypertensive Agents |